Showing results (91-100 of 108) with videos related to
Sort By:
Pageof 11
The Oncologist|December 18, 2023
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery ProtocolIlse A C Spiekman, Birgit S Geurts, Laurien J Zeverijn, et al.European Journal of Cancer (Oxford, England : 1990)|November 9, 2025
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trialNoor Wortelboer, Seamus Kent, Inge R Konings, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery ProtocolKarlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, et al.European Urology Oncology|October 1, 2025
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA AnalysisKaran Parekh, Kim van der Zande, Sarah W S Ng, et al.Cancer Discovery|September 25, 2025
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade TherapyIris L Mimpen, Thomas W Battaglia, Miguel Parra-Martinez, et al.Journal of the National Cancer Institute|November 21, 2025
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trialNoor Wortelboer, Seamus Kent, Hedwig M Blommestein, et al.Nature|November 28, 2024
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancerGabe S Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, et al.JAMA Oncology|February 19, 2026
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical TrialNoor Wortelboer, Annemiek van Ommen-Nijhof, Inge R Konings, et al.ERJ Open Research|October 21, 2022
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) <i>versus</i> intercalated TKI with chemotherapy for <i>EGFR</i>-mutated nonsmall cell lung cancerRolof G P Gijtenbeek, Vincent van der Noort, Joachim G J V Aerts, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery ProtocolBirgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek, et al.Pageof 11